IntegraGen is led by a board of directors who are seasoned leaders in their respective fields of business. Together, the members of the board of directors help to develop policies and strategies which are implemented by IntegraGen's executive team.

Peter Behner

Mr. Peter Behner is a PwC Strategy& Partner GmbH (Germany)  – formerly Booz & Company – and Managing Director of the firms European Healthcare and Public Service Practice. Before joining the firm in 2005, Mr. Behner worked with A.T. Kearney Inc., Trident Consulting Group, Arthur D. Little Inc., and Manufacturing Networks UK. Peter has over 20 years of industry and consulting experience with international corporate clients in the Life Sciences, Provider and Payor Sectors. His areas of focus span across business and corporate strategy, operations and supply chain management as well as business process reengineering among others. Peter is specifically known in the industry for his projects in the area of Commercial Trade Channel management including the development of patient service centers in Europe. Peter  received a Diplom Ingenieur Maschinenbau from RWTH Aachen University and spent two years at the Harvard Business School’s Technical Operations Management department as a Visitor for Individual Studies.

.

Dr. Bernard Courtieu

Dr. Courtieu joined IntegraGen as CEO in September 2007. Prior to this, he had achieved significant success within Gemini Consulting’s Life Sciences division, France, first as Practice Leader, and later on as Vice President. Dr. Courtieu’s tenure with Eurostart, Bossard Gemini Consulting and Cap Gemini Ernst & Young resulted in much hands on experience in how to improve the operational performance of pharmaceutical companies in the fields of Research and Development, Industrial Operations, Supply Chain and Marketing and Information Systems. Later on, Dr. Cortieu took the position as Country Manager, France, at Ariba, the world leader in spend Management, assisting companies in analyzing and managing their corporate spending to achieve maximum buisiness process efficiency. Dr. Courtieu holds an MBA from the Instituto de las Estudios Superiores de la Empresa (IESE) in Barcelona, Spain and he also received his doctorate in Veterinary Medicine from the Ecole Vétérinaire d’Alfort and University Paris XII, France.

.

Emmanuelle Deponge Ph.D.

Biologist by training, Mrs. Emmanuelle Deponge obtained her PhD in Molecular and Cellular Biology in 1994 after being graduated as a Biology Engineer at Polytech in 1989. She obtained a LLM in Intellectual Property Law in 1998. She spent her first 15 years of professional experience in various healthcare and life science organizations including a non-profit patient association (AFM-Telethon), a biotech company in gene therapy (PrimeBiotech) and a cancer institute (Institut Curie). In 2007, she joined APICAP, an independent investment management company, where she developed the venture capital practice dedicated to healthcare and life science. End of 2017, she joined Go Capital as a venture partner in life sciences. She has invested in more than 15 companies in medtech, biotech and other companies like CRO in France and in Europe among which Axes Vision Technology, Biom’Up, Cellix, Echosens, Median technologies, Nanobiotix, Neovacs, ProductLife Group, Repropharm Vet, Trophos and Igyxos.  She invested and was on the board of Trophos when it was sold to Roche (CH) in 2015 and she was on the board of Echosens when it was acquired by FuRui (CN) in 2011. She participated in the quotation on Alternext and Euronext of several companies: Biom’Up, Median Technologies, Nanobiotix and Neovacs.

.

Yannick Sabatin

Yannick Sabatin joined IN-SYNC team in 2010 to the position of CEO Europe. She previously held the position of Associate Director at AEC, and Senior Manager at Bossard Gemini Consulting. Her career started at Boehringer Ingelheim as Product Manager, then at Bistol-Myers Squibb where she was Marketing & innovative products Director. Yannick, as a consultant, is involved in innovation strategies and outcomes driven new business models. She has been leading strategic partnerships in Oncology (research, clinical development and commercial) and has an extensive experience in this area. She advises key oncology leaders to innovate their strategies across cancers and EU countries and to prepare for the future their organizations and teams. Yannick holds a MD from Nantes University (FR) ,and a MBA from Aston University (UK).

 

François Thomas, M.D., Ph.D

Dr. François Thomas is a medical oncologist, former assistant professor at the Gustave Roussy Institute, and holds an MBA from the Massachusetts Institute of Technology. Dr. Thomas is in charge of the Inserm Transfer Initiative (ITI) Funds at Sofimac, where he is venture partner. His multi-disciplinary experience has led him to positions of VP Clinical Development at Ipsen, General Manager of the consultancy Bioserve Ltd, VP of Licensing and Medical Affairs of Genset, and President of Cynthéris. He has also been a venture partner at Atlas Venture and Head of Healthcare Banking at Bryan Garnier. Dr Thomas has dedicated his last 20 years to the creation and development of  biotech companies and is or has been a Director for more than 20 of these companies.

 

Ludovic Tron

Ludovic Tron joined IntegraGen’s Board of Directors in 2018. Mr. Tron began his career in 1997 at Rothschilds bank and is now a managing partner at Natixis Partners. Through this position he acquired much expertise in the fields of Investment Banking, Mergers and also acquisitions. He is a graduate from l’Institut d’Etudes Politiques de Paris (IEP Paris) and of the London School of Economics (LSE).

.

Gerald Wagner, Ph.D.

Dr. Wagner began his commercial career at Agfa-Gevaert, Munich. Having obtained his Ph.D. from the Technical University in Darmstadt, Germany, he rose through the ranks to become President of Agfa Matrix Division at Agfa Corporation, USA and after was elected to the Agfa-Gevaert, Inc board. Dr. Wagner then joined the Diagnostic Systems Business Group of Bayer Corporation as Senior Vice-President, leading the worldwide Laboratory Testing Segment. Once retiring from Bayer, he transferred his experience to the Company by developing a 15-year strategy for the diagnostics group. Since leaving Bayer in 2002, Gerald has had great success as a consultant to a number of companies and organizations. He is an expert at providing international project management, automation and materials management, and long-term strategy expertise.